| Men | Women | ||
---|---|---|---|---|
Without MetS | With MetS | Without MetS | With MetS | |
MetS participants, n (%) | 3973 (88.4) | 522 (11.6) | 6406 (91.1) | 622 (8.9) |
Cancer deaths | 418 | 55 | 251 | 46 |
Parson-Years | 71,444 | 9418 | 120,718 | 11,654 |
Cancer mortality | ||||
 Crude mortality (/1000 person-years) | 5.9 | 5.8 | 2.1 | 3.9 |
 HR-Agea (95% CI) | 1.0 (reference) | 1.11 (0.84–1.48) | 1.0 (reference) | 1.69 (1.23–2.31) |
 HR-Allb (95% CI) | 1.0 (reference) | 1.21 (0.90–1.62) | 1.0 (reference) | 1.69 (1.21–2.36) |
< 65 years old | ||||
 Crude mortality (/1000 person-years) | 3.3 | 3.8 | 1.3 | 2.4 |
 HR-Agea (95% CI) | 1.0 (reference) | 1.14 (0.80–1.61) | 1.0 (reference) | 1.70 (1.14–2.55) |
 HR-Allb (95% CI) | 1.0 (reference) | 1.22 (0.84–1.77) | 1.0 (reference) | 1.66 (1.09–2.55) |
≥ 65 years old | ||||
 Crude mortality (/1000 person-years) | 2.6 | 2.0 | 0.8 | 1.5 |
 HR-Agea (95% CI) | 1.0 (reference) | 1.09 (0.68–1.74) | 1.0 (reference) | 1.71 (1.03–2.83) |
 HR-Allb (95% CI) | 1.0 (reference) | 1.19 (0.73–1.95) | 1.0 (reference) | 1.69 (0.99–2.89) |